Moleculin Biotech, Inc.

Contributing Author

Recent Articles by Moleculin Biotech, Inc.

May-14	Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update MBRX GlobeNewswire
May-12	Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial MBRX GlobeNewswire
May-07	Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast MBRX GlobeNewswire
May-06	Moleculin Announces World Health Organization Approval of "naxtarubicin" as International Non-Proprietary Name for Annamycin MBRX GlobeNewswire
May-05	Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents MBRX GlobeNewswire